I am curious if we will see rapid deployment of one of the rapid point-of-care CRISPR-based detection systems (like https://mammoth.bio/wp-content/uploads/2020/

I am curious if we will see rapid deployment of one of the rapid point-of-care CRISPR-based detection systems (like https://mammoth.bio/wp-content/uploads/2020/02/A-protocol-for-rapid-detection-of-the-2019-novel-coronavirus-SARS-CoV-2-using-CRISPR-diagnostics-SARS-CoV-2-DETECTR.pdf https://mammoth.bio/wp-content/uploads/2020/02/A-protocol-fo...) Probably unlikely, given the understandable emphasis in the medical community on gold-standard diagnostic methods. But if one of these companies can collaborate with the CDC to get their hands on a large number of patient samples for validation, the FDA for quick approval, and a reliable manufacturing partner for scale-up, the possibility exists. (Edit: spelling and added required collaborators to the list)